Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 4/2006

01-12-2006 | Review

The complex role of Fcγ receptors in the pathology of arthritis

Authors: Peter Boross, J. Sjef Verbeek

Published in: Seminars in Immunopathology | Issue 4/2006

Login to get access

Abstract

Autoantibodies of the IgG class and the immune complexes they form are central players in the pathology of rheumatoid arthritis (RA). Receptors for the Fc part of IgG, FcγR constitute one of the main effector mechanisms through which IgG immune complexes exert their action. The different members of the FcγR family exhibit extensive structural homology leading to redundancy in ligand specificity and signal transduction. Moreover, the initiation of effector mechanisms by IgG immune complexes can also be mediated by the complement system. This strong redundancy and high degree of complexity hampers a direct in vivo analysis of antibody effector pathways. Over the last decade, mice deficient for different combinations of FcγR have been generated by gene targeting. These knockout mice provide excellent tools to define the specific contribution of the different FcγR to IgG effector pathways in well-established in vivo mouse models for arthritis. This review will discuss the results of the studies that analyze the role of the different members of the FcγR family in murine arthritis models and their implications for our understanding of the human disease.
Literature
1.
2.
de Vries RR, Huizinga TW, Toes RE (2006) HLA and RA revisited: citrullinated food for the SE hypothesis, the DR6 effect, and NIMA. Hum Immunol 67:454–459PubMedCrossRef
3.
Kroot EJ, de Jong BA, van Leeuwen MA, Swinkelsm H, van den Hoogen FH, van’t Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43:1831–1835PubMedCrossRef
4.
van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 50:709–715PubMedCrossRef
5.
Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386PubMedCrossRef
6.
Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749PubMedCrossRef
7.
Silverman GJ, Weisman S (2003) Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 48:1484–1492PubMedCrossRef
8.
Edwards JC, Cambridge G (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40:205–211CrossRef
9.
Svensson L, Jirholt J, Holmdahl R, Jansson L (1998) B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol 111:521–526PubMedCrossRef
10.
Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, Degott C, Kikutani H, Rajewsky K, Pasquali JL, Benoist C, Mathis D (1999) From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10:451–461PubMedCrossRef
11.
Stuart JM, Dixon FJ (1983) Serum transfer of collagen-induced arthritis in mice. J Exp Med 158:378–392PubMedCrossRef
12.
Schubert D, Maier B, Morawietz L, Krenn V, Kamradt T (2004) Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice. J Immunol 172:4503–4509PubMed
13.
Benoist C, Mathis D (2000) A revival of the B cell paradigm for rheumatoid arthritis pathogenesis? Arthritis Res 2:90–94PubMedCrossRef
14.
Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV (1994) FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76:519–529PubMedCrossRef
15.
Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV (2005) FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23:41–51PubMedCrossRef
16.
Nimmerjahn F, Ravetch JV (2006) Fcgamma receptors: old friends and new family members. Immunity 24:19–28PubMedCrossRef
17.
Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV (1996) Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 379:346–349PubMedCrossRef
18.
Yuasa T, Kubo S, Yoshino T, Ujike A, Matsumura K, Ono M, Ravetch JV, Takai T (1999) Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med 189:187–194PubMedCrossRef
19.
Ioan-Facsinay A, de Kimpe SJ, Hellwig SM, van Lent PL, Hofhuis FM, van Ojik HH, Sedlik C, da Silveira SA, Gerber J, de Jong YF, Roozendaal R, Aarden LA, van den Berg WB, Saito T, Mosser D, Amigorena S, Izui S, van Ommen GJ, van Vugt M, van de Winkel JG, Verbeek JS (2002) FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16:391–402PubMedCrossRef
20.
Fossati-Jimack L, Ioan-Facsinay A, Reininger L, Chicheportiche Y, Watanabe N, Saito T, Hofhuis FM, Gessner JE, Schiller C, Schmidt RE, Honjo T, Verbeek JS, Izui S (2000) Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III. J Exp Med 191:1293–1302PubMedCrossRef
21.
Hazenbos WL, Heijnen IA, Meyer D, Hofhuis FM, Renardel de Lavalette CR, Schmidt RE, Capel PJ, van de Winkel JG, Gessner JE, van den Berg TK, Verbeek JS (1998) Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). J Immunol 161:3026–3032PubMed
22.
Takai T (2005) Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol 25:1–18PubMedCrossRef
23.
Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, Takahashi K, Holers VM, Walport M, Gerard C, Ezekowitz A, Carroll MC, Brenner M, Weissleder R, Verbeek JS, Duchatelle V, Degott C, Benoist C, Mathis D (2002) Arthritis critically dependent on innate immune system players. Immunity 16:157–168PubMedCrossRef
24.
Grant EP, Picarella D, Burwell T, Delaney T, Croci A, Avitahl N, Humbles AA, Gutierrez-Ramos JC, Briskin M, Gerard C, Coyle AJ (2002) Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J Exp Med 196:1461–1471PubMedCrossRef
25.
Wang Y, Kristan J, Hao L, Lenkoski CS, Shen Y, Matis LA (2002) A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collagen-induced arthritis. J Immunol 164:4340–4347
26.
Wang Y, Rollins SA, Madri JA, Matis LA (1995) Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci U S A 92:8955–8959PubMedCrossRef
27.
Schmidt RE, Gessner JE (2005) Fc receptors and their interaction with complement in autoimmunity. Immunol Lett 100:56–67PubMedCrossRef
28.
Trcka J, Moroi Y, Clynes RA, Goldberg SM, Bergtold A, Perales MA, Ma M, Ferrone CR, Carroll MC, Ravetch JV, Houghton AN (2002) Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity 16:861–868PubMedCrossRef
29.
Hazenbos WL, Gessner JE, Hofhuis FM, Kuipers H, Meyer D, Heijnen IA, Schmidt RE, Sandor M, Capel PJ, Daeron M, van de Winkel JG, Verbeek JS (1996) Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity 5:181–188PubMedCrossRef
30.
Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM (1992) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304–309
31.
Sivo J, Politis AD, Vogel SN (1993) Differential effects of interferon-gamma and glucocorticoids on Fc gamma R gene expression in murine macrophages. J Leukoc Biol 54:451–457PubMed
32.
Kannan K, Ortmann RA, Kimpel D (2005) Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 12:167–181PubMedCrossRef
33.
Kouskoff V, Korganow AS, Duchatelle V, Degott C, BenoistC, Mathis D (1996) Organ-specific disease provoked by systemic autoimmunity. Cell 87:811–822PubMedCrossRef
34.
Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S, Sakihama T, Matsutani T, Negishi I, Nakatsuru S, Sakaguchi S (2003) Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426:454–460PubMedCrossRef
35.
Butler DM, Malfait AM, Mason LJ, Warden PJ, Kollias G, Maini RN, Feldmann M, Brennan FM (1997) DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol 159:2867–2876PubMed
36.
Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, Ikuse T, Asano M, Iwakura Y (2000) Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 191:313–320PubMedCrossRef
37.
van Lent PL, van Vuuren AJ, Blom AB, Holthuysen AE, van de Putte LB, van de Winkel JG, van den Berg WB (2000) Role of Fc receptor gamma chain in inflammation and cartilage damage during experimental antigen-induced arthritis. Arthritis Rheum 43:740–752PubMedCrossRef
38.
Nabbe KC, Blom AB, Holthuysen AE, Boross P, Roth J, Verbeek S, van Lent PL, van den Berg WB (2003) Coordinate expression of activating Fc gamma receptors I and III and inhibiting Fc gamma receptor type II in the determination of joint inflammation and cartilage destruction during immune complex-mediated arthritis. Arthritis Rheum 48:255–265PubMedCrossRef
39.
Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B (1980) Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283:666–668PubMedCrossRef
40.
Kleinau S, Martinsson P, Heyman B (2000) Induction and suppression of collagen-induced arthritis is dependent on distinct fcgamma receptors. J Exp Med 191:1611–1616PubMedCrossRef
41.
Diaz DS, Andren M, Martinsson P, Verbeek JS, Kleinau S (2002) Expression of FcgammaRIII is required for development of collagen-induced arthritis. Eur J Immunol 32:2915–2922CrossRef
42.
van Lent PL, Holthuysen AE, Van Den Bersselaar LA, van Rooijen N, Joosten LA, van de Loo FA, van de Putte LB, van den Berg WB (1996) Phagocytic lining cells determine local expression of inflammation in type II collagen-induced arthritis. Arthritis Rheum 39:1545–1555PubMed
43.
Andren M, Xiang Z, Nilsson G, Kleinau S (2006) FcgammaRIII-expressing macrophages are essential for development of collagen-induced arthritis. Scand J Immunol 63:282–289PubMedCrossRef
44.
Kaplan CD, O’Neill SK, Koreny T, Czipri M, Finnegan A (2002) Development of inflammation in proteoglycan-induced arthritis is dependent on Fc gamma R regulation of the cytokine/chemokine environment. J Immunol 169:5851–5859PubMed
45.
Kaplan CD, Cao Y, Verbeek JS, Tunyogi-Csapo M, Finnegan A (2005) Development of proteoglycan-induced arthritis is critically dependent on Fcgamma receptor type III expression. Arthritis Rheum 52:1612–1619PubMedCrossRef
46.
Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM (1992) Induction of arthritis with monoclonal antibodies to collagen. J Immunol 148:2103–2108PubMed
47.
Kagari T, Tanaka D, Doi H, Shimozato T (2003) Essential role of Fc gamma receptors in anti-type II collagen antibody-induced arthritis. J Immunol 170:4318–4324PubMed
48.
Nandakumar KS, Andren M, Martinsson P, Bajtnerm E, Hellstrom S, Holmdahl R, Kleinau S (2003) Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcgammaRIIB. Eur J Immunol 33:2269–2277PubMedCrossRef
49.
Banda NK, Thurman JM, Kraus D, Wood A, Carroll MC, Arend WP, Holers VM (2006) Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J Immunol 177:1904–1912PubMed
50.
Wipke BT, Wang Z, Nagengast W, Reichert DE, Allen PM (2004) Staging the initiation of autoantibody-induced arthritis: a critical role for immune complexes. J Immunol 172:7694–7702PubMed
51.
Grant EP, Picarella D, Burwell T, Delaney T, Croci A, Avitahl N, Humbles AA, Gutierrez-Ramos JC, Briskin M, Gerard C, Coyle AJ (2002) Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J Exp Med 196:1461–1471PubMedCrossRef
52.
Tanaka D, Kagari T, Doi H, Shimozato T (2006) Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis. Immunology 119(2):195–202PubMedCrossRef
53.
Maccioni M, Zeder-Lutz G, Huang H, Ebel C, Gerber P, Hergueux J, Marchal P, Duchatelle V, Degott C, van Regenmortel M, Benoist C, Mathis D (2002) Arthritogenic monoclonal antibodies from K/B×N mice. J Exp Med 195:1071–1077PubMedCrossRef
54.
Corr M, Crain B (2002) The role of FcgammaR signaling in the K/B × N serum transfer model of arthritis. J Immunol 169:6604–6609PubMed
55.
Ji H, Gauguier D, Ohmura K, Gonzalez A, Duchatelle V, Danoy P, Garchon HJ, Degott C, Lathrop M, Benoist C, Mathis D (2001) Genetic influences on the end-stage effector phase of arthritis. J Exp Med 194:321–330PubMedCrossRef
56.
Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB (2002) Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 297:1689–1692PubMedCrossRef
57.
Wipke BT, Allen PM (2001) Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol 167:1601–1608PubMed
58.
Binstadt BA, Patel PR, Alencar H, Nigrovic PA, Lee DM, Mahmood U, Weissleder R, Mathis D, Benoist C (2006) Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat Immunol 7:284–292PubMedCrossRef
59.
Finkelman FD, Rothenberg ME, Brandt EB, Morris SC, Strait RT (2005) Molecular mechanisms of anaphylaxis: lessons from studies with murine models. J Allergy Clin Immunol 115:449–457PubMedCrossRef
60.
Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, Gravallese E, Mathis D, Benoist C (2002) Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 196:77–85PubMedCrossRef
61.
van Lent PL, Nabbe K, Blom AB, Holthuysen AE, Sloetjes A, van de Putte LB, Verbeek S, van den Berg WB (2001) Role of activatory Fc gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in inflammation and cartilage destruction during experimental antigen-induced arthritis. Am J Pathol 159:2309–2320PubMed
62.
van Meurs JB, van Lent PL, Holthuysen AE, Singer II, Bayne EK, van den Berg WB (1999) Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum 42:1128–1139PubMedCrossRef
63.
van den Broek MF, van den Berg WB, van de Putte LB (1988) The role of mast cells in antigen induced arthritis in mice. J Rheumatol 15:544–551PubMed
64.
van Lent PL, Holthuysen AE, van Den BL, van Rooijen N, van de Putte LB, van den Berg WB (1995) Role of macrophage-like synovial lining cells in localization and expression of experimental arthritis. Scand J Rheumatol Suppl 101:83–89PubMed
65.
van Lent P, Nabbe KC, Boross P, Blom AB, Roth J, Holthuysen A, Sloetjes A, Verbeek S, van den Berg W (2003) The inhibitory receptor FcgammaRII reduces joint inflammation and destruction in experimental immune complex-mediated arthritides not only by inhibition of FcgammaRI/III but also by efficient clearance and endocytosis of immune complexes. Am J Pathol 163:1839–1848PubMed
66.
Blom AB, van Lent PL, van Vuuren H, Holthuysen AE, Jacobs C, van de Putte LB, van de Winkel JG, van den Berg WB (2000) Fc gamma R expression on macrophages is related to severity and chronicity of synovial inflammation and cartilage destruction during experimental immune-complex-mediated arthritis (ICA). Arthritis Res 2:489–503PubMedCrossRef
67.
Nabbe KC, Blom AB, Holthuysen AE, Boross P, Roth J, Verbeek S, van Lent PL, van den Berg WB (2003) Coordinate expression of activating Fc gamma receptors I and III and inhibiting Fc gamma receptor type II in the determination of joint inflammation and cartilage destruction during immune complex-mediated arthritis. Arthritis Rheum 48:255–265PubMedCrossRef
68.
van Lent PL, van den Hoek AE, Van Den Bersselaar LA, Spanjaards MF, van Rooijen N, Dijkstra CD, van de Putte LB, van den Berg WB (1993) In vivo role of phagocytic synovial lining cells in onset of experimental arthritis. Am J Pathol 143:1226–1237PubMed
69.
Nabbe KC, van Lent PL, Holthuysen AE, Kolls JK, Verbeek S, van den Berg WB (2003) FcgammaRI up-regulation induced by local adenoviral-mediated interferon-gamma production aggravates chondrocyte death during immune complex-mediated arthritis. Am J Pathol 163:743–752PubMed
70.
Nabbe KC, Boross P, Holthuysen AE, Sloetjes AW, Kolls JK, Verbeek S, van Lent PL, van den Berg WB (2005) Joint inflammation and chondrocyte death become independent of Fcgamma receptor type III by local overexpression of interferon-gamma during immune complex-mediated arthritis. Arthritis Rheum 52:967–974PubMedCrossRef
71.
Nieto A, Caliz R, Pascual M, Mataran L, Garcia S, Martin J (2000) Involvement of Fcgamma receptor IIIA genotypes in susceptibility to rheumatoid arthritis. Arthritis Rheum 43:735–739PubMedCrossRef
72.
Chen JY, Wang CM, Wu JM, Ho HH, Luo SF (2006) Association of rheumatoid factor production with FcgammaRIIIa polymorphism in Taiwanese rheumatoid arthritis. Clin Exp Immunol 144:10–16PubMedCrossRef
73.
Matsumoto I, Zhang H, Muraki Y, Hayashi T, Yasukochi T, Kori Y, Goto D, Ito S, Tsutsumi A, SumidaT (2005) A functional variant of Fcgamma receptor IIIA is associated with rheumatoid arthritis in individuals who are positive for anti-glucose-6-phosphate isomerase antibodies. Arthritis Res Ther 7:R1183–R1188PubMedCrossRef
74.
Kastbom A, Ahmadi A, Soderkvist P, Skogh T (2005) The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: increased susceptibility and severity in male patients (the Swedish TIRA project). Rheumatology (Oxford) 44:1294–1298CrossRef
75.
Hogarth PM (2002) Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol 14:798–802PubMedCrossRef
76.
Tan SC, Mottram PL, van de Velde NC, Powell MS, Power D, Slocombe RF, Wicks IP, Campbell IK, McKenzie SE, Brooks M, Stevenson AW, Hogarth PM (2005) Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fcgamma receptor IIa-transgenic mice. Arthritis Rheum 52:3220–3229CrossRef
77.
Wijngaarden S, van de Winkel JG, Jacobs KM, Bijlsma JW, Lafeber FP, van Roon JA (2004) A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. Arthritis Rheum 50:3878–3887PubMedCrossRef
78.
Radstake TR, Blom AB, Sloetjes AW, van Gorselen EO, Pesman GJ, Engelen L, Torensma R, van den Berg WB, Figdor CG, van Lent PL, Adema GJ, Barrera P (2004) Increased FcgammaRII expression and aberrant tumor necrosis factor alpha production by mature dendritic cells from patients with active rheumatoid arthritis. Ann Rheum Dis 63:1556–1563PubMedCrossRef
79.
80.
Johansson AC, Sundler M, Kjellen P, Johannesson M, Cook A, Lindqvist AK, Nakken B, Bolstad AI, Jonsson R, Alarcon-Riquelme M, Holmdahl R (2001) Genetic control of collagen-induced arthritis in a cross with NOD and C57BL/10 mice is dependent on gene regions encoding complement factor 5 and FcgammaRIIb and is not associated with loci controlling diabetes. Eur J Immunol 31:1847–1856PubMedCrossRef
81.
Yanni G, Whelan A, Feighery C, Bresnihan B (1994) Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Ann Rheum Dis 53:39–44PubMedCrossRef
82.
van der Helm-van Mil AH, Wesoly JZ, Huizinga TW (2005) Understanding the genetic contribution to rheumatoid arthritis. Curr Opin Rheumatol 17:299–304PubMedCrossRef
83.
Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, Smith J, Mangion J, Roberton-Lowe C, Marshall AJ, Petretto E, Hodges MD, Bhangal G, Patel SG, Sheehan-Rooney K, Duda M, Cook PR, Evans DJ, Domin J, Flint J, Boyle JJ, Pusey CD, Cook HT (2006) Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 439:851–855PubMedCrossRef
84.
Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S (2006) Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312:1669–1672PubMedCrossRef
85.
van Lent PL, Grevers L, Lubberts E, de Vries TJ, Nabbe KC, Verbeek JS, Oppers B, Sloetjes A, Blom AB, van den Berg WB (2006) Fcg receptors directly mediate cartilage but not bone destruction: uncoupling of cartilage damage from bone erosion and joint inflammation. Arthritis Rheum (in press)
Metadata
Title
The complex role of Fcγ receptors in the pathology of arthritis
Authors
Peter Boross
J. Sjef Verbeek
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 4/2006
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-006-0049-9

Other articles of this Issue 4/2006

Seminars in Immunopathology 4/2006 Go to the issue

Review

IgA and IgA-specific receptors in human disease: structural and functional insights into pathogenesis and therapeutic potential

Review

Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity

Review

Fc gamma receptors and cancer

Review

FcγRII and multi-system autoimmune disease

Review

IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity

Review

Activating and inhibitory FcγRs in autoimmune disorders
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits